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Abstract 
Genetic studies show that LRRK2, and not its closest paralogue LRRK1, is linked to 
Parkinson’s disease. To understand this at the cellular level, we searched for LRRK1- 
and LRRK2-specific cellular processes by identifying their distinct interacting 
proteins. Therefore, a protein micoarray-based interaction screen was performed with 
recombinant LRRK1 and LRRK2. In parallel, co-immunoprecipitation followed by 
mass spectrometry was performed from SH-SY5Y neuroblastoma cell lines stably 
expressing 3xFlag-LRRK1 or 3xFlag-LRRK2. We identified a set of LRRK1- and 
LRRK2-specific as well as common interactors. One of our most prominent findings 
was that both screens pointed to epidermal growth factor receptor (EGF-R) as a 
LRRK1-specific interactor, while 14-3-3 proteins were LRRK2-specific. This is 
consistent with phosphosite mapping of LRRK1, revealing phosphosites outside of 
14-3-3 consensus binding motifs. To assess the functional relevance of these 
interactions, SH-SY5Y-LRRK1 and -LRRK2 cell lines were treated with LRRK2 
kinase inhibitors which disrupt 14-3-3 binding, or with EGF, an EGF-R agonist. 
Redistribution of LRRK2, not LRRK1, from diffuse cytoplasmic to filamentous 
aggregates was observed after inhibitor treatment. Similarly, EGF induced 
translocation of LRRK1, but not of LRRK2, to endosomes. Our study confirms that 
LRRK1 and LRRK2 can carry out distinct functions by interacting with different 
cellular proteins. 
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Introduction 
 
Since the identification of mutations in leucine-rich repeat kinase 2 (LRRK2) linked 
to familial forms of Parkinson’s disease (PD) (Paisan-Ruiz et al., 2004; Zimprich et 
al., 2004), LRRK2 has revealed itself as one of the most important contributors to PD 
pathogenesis. Mutations in LRRK2 are a common cause of familial forms of PD 
where the phenotype is clinically similar to that of sporadic PD (Haugarvoll et al., 
2008; Healy et al., 2008). In addition, genetic variation at the LRRK2 locus is also 
associated with sporadic PD (Satake et al., 2009; Simón-Sánchez et al., 2009; Ross et 
al., 2011). However, the precise cellular processes regulated by LRRK2 and the exact 
nature of its dysfunction in the etiology of disease are incompletely understood. 
LRRK2 is a member of the ROCO family of multidomain proteins which are 
characterized by the presence of a Ras of complex (ROC) protein domain and an 
adjacent C-terminal of ROC domain (COR) (Lewis, 2009). LRRK2’s closest 
paralogue is LRRK1 which displays a similar domain organization: besides the 
signature ROC-COR domains both proteins also encode a serine-threonine kinase 
domain C-terminal of ROC-COR and N-terminal leucine-rich and ankyrin-like 
repeats (Marín, 2006; 2008; Civiero et al., 2012). Differences between both proteins 
are that LRRK2 additionally displays an N-terminal segment encoding armadillo-like 
repeats, while theWD40 domain present in the LRRK2 C-terminus, is absent in the 
equivalent section of LRRK1 (Marín, 2006; 2008; Civiero et al., 2012) (Figure S1B). 
There is no genetic support for the involvement of LRRK1 in the pathogenesis of PD, 
suggesting that LRRK2 has unique properties that are relevant for the disease process 
(Haugarvoll et al., 2007; Taylor et al., 2007). We have previously shown that the 
detrimental effects of mutations in LRRK2 are not reproduced by introducing 
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equivalent mutations in LRRK1 (Greggio et al., 2007). Collectively, these 
observations suggest that although the two proteins have similar modular organization, 
LRRK1 and LRRK2 have distinct properties and these may be important for disease 
pathogenesis. 
 
However, LRRK1 has also been shown to interact with LRRK2 (Klein et al., 2009; 
Dächsel et al., 2010). This interaction and the high degree of homology between the 
two proteins, indicates that LRRK1 may be involved in the LRRK2 signaling network. 
In order to better understand the relationship between cellular signaling functions of 
LRRK1 and LRRK2, we have screened for protein-protein interaction partners of 
LRRK1 and LRRK2 ((Beilina et al., 2014) and Figure 1). These screens pointed to a 
LRRK1-specific interaction with EGF-R and a LRRK2-specific interaction with 14-3-
3, confirming previous reports (Nichols et al., 2010; Hanafusa et al., 2011). In this 
study, we further characterize these two interactions, in particular the crosstalk 
between the two pathways. We show that these interactions are specific for each 
LRRK and that they mediate specific, independently occurring cellular translocation 
processes for each LRRK. In turn, these results point to segregated functional 
complexes in the LRRK1 and LRRK2 signaling networks in mammalian cells. 
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Methods 
Constructs and antibodies 
Eukaryotic expression constructs of 3xFlag tagged LRRK1 (pCHMWS-3xFlag-
LRRK1) and 3xFlag tagged LRRK2 (pCHMWS-3xFlag-LRRK2) have been 
previously described (Daniëls et al., 2010). To generate eGFP tagged versions of 
these constructs, the 3xFlag tag was excised (using restriction sites NheI and BamHI) 
and an eGFP sequence (excised from the peGFP-C1 plasmid using restriction sites 
NheI and BglII) was ligated in the place, yielding the pCHMWS-eGFP-LRRK1 and 
pCHMWS-eGFP-LRRK2 constructs. 
For constructs encoding 2xMyc tagged 14-3-3 isoforms (pCMV-3B-2xMyc-14-3-3-
zeta and pCMV-3B-2xMyc-14-3-3-beta), 14-3-3 beta and zeta were amplified from 
pEBG-6P1 14-3-3 beta and EBG2T 14-3-3 zeta vectors (kindly provided by Prof. 
Dario Alessi, University of Dundee, UK) using Pfu polymerase (Promega, Madison, 
WI, USA), cloned into pCR8GW/TOPO (Life Technologies, Grand Island, NY, USA), 
and subcloned into 2xMyc gateway destination vector (Greggio et al., 2007). The 
PCR primers used are: Zeta-FOR: ATGGATAAAAATGAGCTGGTTCAG, Zeta-
REV: TTAATTTTCCCCTCCTTCTCCTGC, Beta-FOR: 
ATGACAATGGATAAAAGTGAGCTG, Beta-REV: 
TTAGTTCTCTCCCTCCCCAGCGTC. 
Myc-tagged EGF-R (pLPCX-EGF-R-Myc) was kindly provided by Dr. Guha 
(University of Toronto, Canada) (Gajadhar and Guha, 2010). 
To generate knockdown constructs, short hairpin sequences targeting LRRK1 
(reference sequence NM_024652) or LRRK2 (reference sequence NM_198578.3) 
were cloned into microRNA sequences in the 3’UTR region of a blasticidin resistance 
gene under control of the SFFV promoter in lentiviral vector transfer plasmids (see 
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Supplementary Table 1 for sequences of cloning oligonucleotides), yielding the 
following constructs: LV_miR_LRRK1_3351-sh3, LV_miR_LRRK1_4366-sh2, 
LV_miR_LRRK1_6091-sh4, LV_miR_LRRK1_6734-sh1, LV_miR_LRRK2_2384-
sh5, LV_miR_LRRK2_6251-sh3, LV_miR_LRRK2_7814-sh1, (note that the number 
immediately following the gene name refers to the position on the reference sequence 
of the first base of the short hairpin sequence). Controls for the knockdown vectors 
included empty vector control as well as vectors encoding short hairpin sequences 
targeting firefly luciferase (Osório et al., 2013). 
Antibodies used in this study are: monoclonal mouse anti-Myc antibody (9e10, Roche, 
Basel, Switzerland), monoclonal mouse anti-Flag antibody (Sigma Aldrich), 
polyclonal rabbit anti-EGFR antibody (Cell Signaling Technology, Beverly, MA, 
USA), rabbit polyclonal pan 14-3-3 antibody (Santa Cruz Biotechnology, Dallas, 
Texas, USA), rabbit monoclonal Hsp90 antibody (Cell Signaling Technology), rat 
monoclonal Hsc70 antibody (Abcam, Cambridge, UK), rabbit polyclonal BAG5 
antibody (Sigma Aldrich) and monoclonal mouse anti-early endosome antigen 1 
(EEA1, BD Biosciences, Erembodegem, Belgium). Polyclonal sheep anti-LRRK1 
was obtained from Prof. Dario Alessi (University of Dundee, Dundee, UK). Anti-
LRRK2 antibodies used were the rabbit monoclonal antibodies C41-2 and UDD3 
(antibody produced by Epitomics with the support of the Michael J. Fox Foundation) 
as well as the mouse monoclonal antibody N138/6 (antibody produced by Neuromab 
with the support of the Michael J. Fox Foundation) (Davies et al., 2013). 
 
Cell culture and transfection 
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Life 
technologies) supplemented with 8% Fetal Bovine Serum (FCS, Harlan Sera-Lab Ltd., 
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Indianapolis, USA) and 50 µg/ml gentamycin (Life technologies) at 37°C in a 
humidified atmosphere containing 5% CO2. SH-SY5Y human neuroblastoma cells 
were cultured in DMEM supplemented with 15% FCS, 50 µg/ml gentamycin and 
non-essential amino acids (100X, Life technologies) also at 37°C with 5% CO2. 
Transient expression was performed by transfecting plasmids with linear 
polyethylenimine (Polysciences Europe GmbH, Eppelheim, Germany) according to 
the manufacturer’s protocol for 24-48 h. 
 
Protein microarray screen for LRRK1 and LRRK2 interaction partners 
Detailed methodology for the protein microarray experiments has been described 
previously (Beilina et al., 2014). For the current analysis, protoarrays
®
 version 5.30 
(Life technologies) were probed with 6 µg purified 3xFlag-GFP; 3xFlag-LRRK1 or 
3xFlag-LRRK2 in buffer alone. Arrays were probed with antibodies against the 
FLAG tag and scanned.  
To understand the specific interactions for each protein, we first filtered Z-scores, 
which represent the number of standard deviations for the signal of each protein 
against background on that array, for LRRK1 or LRRK2 against Flag-eGFP, thus 
removing common false-positive interactors. We then took the filtered lists of Z-
scores and performed direct comparisons for both proteins. The raw data for LRRK1 
and LRRK2 is included in the supporting information. 
 
Affinity purification of LRRK complexes followed by mass spectrometry 
identification of complex components 
HEK293T cells stably expressing 3xFlag-LRRK1 or 3xFlag-LRRK2 were expanded 
up to twelve T150 tissue culture flasks (Sigma Aldrich) per condition. When the 
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flasks reached 100% confluency, cells were trypsinized and collected in a 50 ml 
falcon tube per condition. After rinsing two times with PBS, lysis was performed for 
20 minutes on ice in 10 ml Lysis buffer (25 mM Tris/HCl pH 7.4, 150 mM NaCl, 5 
mM MgCl2, 0.1% (v/v) Triton X-100 and protease inhibitor cocktail (Roche)). 
Lysates were centrifuged at 4°C for 10 minutes at 14000xg and cleared lysates were 
incubated overnight with anti-Flag M2 agarose beads (Sigma Aldrich) at 4°C on a 
rotator. Beads were washed 4 times with Lysis buffer. After washing, 
immunoprecipitates were eluted in elution solution (50% (v/v) acetonitrile, 1% (v/v) 
Formic acid) and supernatans were dried in a speedvac. The dried pellets were 
dissolved in SDS loading buffer and the isolated protein complexes were fractionated 
with SDS-PAGE. Coomassie brilliant blue staining was performed to visualize 
proteins and sample lanes were cut into five equal gel pieces, followed by an 
overnight in-gel trypsin digestion at 37°C. Extracted peptides were further purified 
using C18 matrix and analyzed by a 4800 MALDI-TOF/TOF Mass Analyzer (AB 
SCIEX, Framingham, MA, USA). List of identified proteins were compiled based on 
a protein identification probability of at least 80% as determined by Scaffold™ 
software v3.6.3 (Proteome software, Portland, OR, USA). 
 
Co-immunoprecipitation and protein purification  
For co-immunoprecipitation on overexpressed proteins, HEK293T cells stably 
expressing 3xFlag-LRRK1 or LRRK2 were transfected with pCMV-3B-2xMyc-14-3-
3-zeta and pLPCX-EGF-R-Myc with polyethyleneimine and lysed after 48-72 hours 
in Co-IP buffer (10 mM Tris/HCl pH 7.4, 150 mM NaCl, 10 mM MgCl2, 0.5% Triton 
X-100 and protease inhibitor cocktail (Roche)). Lysates were centrifuged at 4°C for 
10 minutes at 14000 x g. Cleared lysates were incubated for 3 to 18 hours with anti-
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Flag M2 agarose beads at 4°C on a rotator. Beads were washed 4 times with Co-IP 
buffer. After washing, immunoprecipitates were eluted by addition of 2x SDS loading 
buffer. 
For co-immunoprecipitation of endogenous Hsc70, Hsp90 and BAG5, HEK293T 
cells were transfected with 2 µg of 3xFlag-LRRK1, 3xFlag-LRRK2 or GUS-3xFlag 
with lipofectamine. 24 hours after transfection cells were lysed for 30 minutes on a 
rotator in Co-IP buffer 2 (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 0,3 % 
Triton X-100, 10 % Glycerol, Protease (EDTA free) and phosphatase inhibitors). 
Lysates were centrifuged at 4°C for 10 minutes at 14000 x g. 20 µg Protein G beads 
were added to each tube and mixed for 30 minutes at 4°C followed by the addition of 
20 µl flag beads. Beads were washed with Co-IP buffer 3 (same as Co-IP buffer 2 
except Triton X-100 concentration is 0,1 % instead of 0,3 % and 0,1 mM nucleotide is 
added) and proteins were eluted with 30 µl of 3xFlag peptide in Tris 25 mM pH 7.5, 
150 mM NaCl, MgCl2 10 mM, dithiothreitol (DTT) 2 mM, beta-glycerophosphate 5 
mM, Na3VO4 0.1 mM and 0.02% Triton.  
 
Samples were resolved on 3–8% Tris-Acetate or 10% Bis-Tris gels (Life 
technologies) and subsequently blotted onto PVDF membranes (Bio-Rad, Hercules, 
CA, USA). Blots were probed with rabbit polyclonal 14-3-3 antibody (Santa Cruz 
Biotechnology, 1:500), rabbit EGF-R antibody (Cell Signaling Technology, Danvers, 
Massachusetts, USA, 1:2000), rat Hsc70 (Abcam, 1:2000), rabbit Hsp90 (Cell 
Signaling Technology, 1:2000) and rabbit BAG5 (Sigma Aldrich, 1:2000). 
Immunoreactive proteins were visualized using the enhanced chemiluminescence plus 
(ECL plus) technique (GE Healthcare, Little Chalfont, England). 
 
 11 
Assessment of LRRK2 kinase inhibitor and epidermal growth factor induced 
subcellular translocation 
To test translocation of LRRK1 or LRRK2, cells stably overexpressing eGFP-LRRK1 
or eGFP-LRRK2 were plated out on 12 mm coverslips in a 24-well plate or in 8-well 
chamber slides. To test LRRK2 kinase inhibitor induced translocation, cells were 
treated with 1 µM of the LRRK2 kinase inhibitor LRRK2-IN1 (obtained from 
Division for Signal Transduction, University of Dundee, with support from the 
Michael J. Fox Foundation) by diluting the compound into the cell culture medium to 
its end concentration and incubating the cells for 60 minutes at 37°C. Cells were fixed 
and mounted onto cover slips as described in supporting information. Cells were 
imaged using a confocal laser scanning microscope (Fluoview 1000, Olympus) and 
manually scored for translocation to filamentous structures, based on the presence of 
one or more filamentous accumulations of eGFP-LRRK1 or eGFP-LRRK2. 
To test translocation of LRRK1 or LRRK2 under influence of epidermal growth 
factor (EGF), cells were placed on serum-free DMEM for 12-16 hours, then treated 
with 100 ng/ml of EGF or 100 ng/ml EGF-Rh and incubated at 37°C for the time 
points indicated in the results section (0-30 minutes). Cells were then washed two 
times with PBS, fixed in formaldehyde 4% w/v in PBS and mounted onto cover slips 
as described in supporting information. Cells were imaged using a confocal laser 
scanning microscope (Fluoview 1000, Olympus) and manually scored for the 
presence of endosome-like accumulations positive for LRRK1 or LRRK2. Cells were 
scored positive based on the presence of at least five endosomal accumulations of 
eGFP-LRRK1 or eGFP-LRRK2 per cell. For experiments using fluorescently labeled 
EGF, cells displaying eGFP-LRRK1 or eGFP-LRRK2 and EGF positive endosomes 
(at least 5 LRRK/EGF double positive endosomes per cell) were scored positive. For 
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each condition tested, at least 3 wells with 20-100 cells per well were scored. Results 
were expressed as the percentage of positively scored cells. All conditions were tested 
and quantified in triplicate or more. 
 
Statistical analysis 
All quantitative data are expressed as means ± SEM. Significance of differences was 
assessed by Student’s t test or by one-way ANOVA followed by a Dunnett post-test 
comparing each experimental group to the LRRK2 control group or two-way 
ANOVA (for EGF induced translocation, using time and treatment as parameters) 
followed by Bonferroni post tests comparing each experimental group to the LRRK2 
control group. Results were considered statistically significant if p<0.05. 
 
More supporting methods are available in Supporting Information.  
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Results 
 
Protein-protein interaction (PPI) screens for LRRK1 and LRRK2 using protein 
microarray and Affinity Purificiation - Mass Spectrometry (AP-MS) 
To identify direct interaction partners of LRRK1, we probed protein microarrays 
containing ~9000 human proteins with soluble full-length 3xFlag-LRRK1, 3xFlag-
LRRK2 and as an internal control 3xFlag-GFP, prepared as previously described 
(Civiero et al., 2012). Interaction strengths were ranked by Z-score (Figure 1A-B). 
Because we were specifically interested in the differential interaction partners of 
LRRK1 and LRRK2, we compared the data against a previously reported set of 
experiments with LRRK2 (Hanafusa et al., 2011; Ishikawa et al., 2012), having 
filtered both lists to remove false positive non-specific interactors by removing 
proteins that bound to 3xFlag-tagged eGFP. In this analysis, we found the two 
proteins to have distinct interacting partners (Figure 1A). Using a Z-score cutoff of 3, 
we identified 30 candidate proteins unique for LRRK1 (Supporting Table 1A), 57 
proteins unique for LRRK2 (Supporting Table 1B) and 16 shared proteins 
(Supporting Table 1C, all raw data files for LRRK1 are included as supplemental 
material, raw data files of LRRK2 are included in (Beilina et al., 2014)). Some of the 
unique interacting proteins included EGFR for LRRK1 and 14-3-3 proteins for 
LRRK2 (Figure 1 A and B).  
To identify additional protein complexes and to potentially confirm some of the 
protein microarray hits, we used in parallel a second unbiased approach, namely 
affinity purification of 3xFlag-tagged LRRK1 or LRRK2 from stable SH-SY5Y cell 
lines followed by liquid chromatography tandem mass spectrometry (LC-MS/MS) 
(Figure 1C). Using this approach, we identified 16 potential LRRK1 interacting 
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proteins (Supporting Table 2A), of which five were shared with LRRK2 (Supporting 
Table 2C). On top of the five shared ones, we also identified 15 LRRK2-specific 
interaction partners (Supporting Table 2B). Interacting proteins identified in 3xFlag-
LRRK1 or LRRK2 complexes included the EGF-R adaptor protein Grb2 for LRRK1 
and 14-3-3 proteins for LRRK2, confirming the protein microarray findings. Venn 
diagrams summarizing the overlap of identified proteins between both LRRKs for 
each protein-protein interaction screen or between both screens for each LRRK are 
given in Figure 1D. 
Taken together, our two different screening approaches led to the identification of 
several LRRK1/2-specific as well as common interactors. Using the protein 
microarray approach, the number of potential interactors identified is higher 
compared to the number identified with the AP-MS approach (Figure 1D, Supporting 
tables 1A-C and 2A-C). The protein microarray technique uses recombinant proteins 
only (both as probe as well as spotted on the chip). Therefore, interactions will be 
elucidated even for proteins with low abundance in cells and cellular regulation of 
interactions such as posttranslational modifications or formation of higher order 
complexes is absent. The AP-MS technique, on the other hand, is dependent on the 
proteome of the cellular system used and will more likely recover interactions with 
abundant proteins only. Remarkably, there is also only minor overlap between the hits 
identified in the two different approaches. This can be explained by the different 
nature of the screening technique and implies that all results obtained using these 
techniques should be carefully validated.  
It should be noted that sometimes, known interactors are not always recovered. For 
instance, in this study, we identified Bcl-2 athanogene (BAG) proteins only when 
LRRK1 was probed to the arrays, while in the recent study of Beilina et al. BAGs 
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were also picked up when array were probed with LRRK2 (Beilina et al., 2014). This 
implies a significant false negative rate for the assays and again points to a careful 
interpretation of the results and highlights the need for validation of the hits. For the 
AP/MS technique, false positive and false negative hits have begun to be 
characterized (Mellacheruvu et al., 2013). Together, the LRRK1:EGF-R and 
LRRK2:14-3-3 interactions emerge as the top interactions from the combined results 
of both PPI screens. 
 
Confirmation of specific interactions LRRK1:EGF-R and LRRK2:14-3-3 and 
common LRRK interactors Hsc70, BAG5 and HSP90 
Because two different protein-protein interaction screens pointed to EGF-R as a 
specific interactor of LRRK1 and not LRRK2, and 14-3-3 proteins as specific 
interactors of LRRK2 and not LRRK1, we chose these proteins for further validation. 
Human Embryonic Kidney (HEK) 293T cell lines stably expressing 3xFlag-LRRK1 
or LRRK2 were transfected with Myc-tagged 14-3-3ζ or EGF-R (Civiero et al., 
2012; Taymans et al., 2013). Cell extracts were used to immunoprecipitate LRRK1 
and LRRK2 with an anti-Flag antibody, followed by detection of EGF-R and 14-3-3ζ. 
As predicted from the two initial screens, EGF-R co-immunoprecipitated with 
LRRK1 but not with LRRK2 (Figure 2A). Similarly, we co-immunoprecipitated 14-3-
3ζ with LRRK2 but not with LRRK1 (Figure 2B). In parallel, we also tested three 
proteins that were identified as common interactors: Hsc70, BAG5 and Hsp90. 
HEK293T cells were therefore transfected with 3xFlag-LRRK1 and 3xFlag-LRRK2. 
Cell extracts were used to immunoprecipitate LRRK1 and LRRK2 using an anti-Flag 
antibody. Western blot analysis with specific antibodies against the protein of interest 
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showed that endogenous Hsc70, Hsp90 and BAG5 interacted with LRRK1 as well as 
LRRK2, confirming our protein microarray and AP-MS results (Figure 2C).  
 
Differential protein interactions of LRRK proteins correlates with differential 
protein phosphorylation 
Both LRRKs are phosphorylated in mammalian cells (Greggio et al., 2007; Taymans 
et al., 2013), but the absence of residues in LRRK1 equivalent to LRRK2 
phosphoresidues S910/S935 (Figure S1B) suggest that different residues must be 
phosphorylated in each protein. Furthermore, given the requirement for LRRK2-
specific residues to be phosphorylated to bind 14-3-3 proteins (Civiero et al., 2012; 
Taymans et al., 2013), we hypothesized that differential phosphorylation might be 
important for the identified differences in protein binding seen in the screening 
approaches and validated above (Greggio et al., 2007). In order to compare the 
phosphoresidues in both proteins, we used a phosphoproteomic approach on LRRK1 
and LRRK2 affinity purified from stable HEK293T-3xFlag-LRRK1 or LRRK2 cell 
lines. Proteins were fractionated by SDS-PAGE and purity was assessed by 
Coomassie brilliant blue staining (Figure S1A). Mass spectrometry (MS) analysis 
confirmed phosphorylation of LRRK2 at several previously reported sites such as 
S910, S955 and S973 (Figure S1B-C) (Lobbestael et al., 2012). We also identified a 
novel phosphorylation site at S1058, which is located in the third leucine-rich repeat 
of the LRR domain (Vancraenenbroeck et al., 2012). However, our analysis of 
LRRK1 cellular phosphorylation identified S249 at the end of the ankyrin repeat 
domain, S1074 and T1075 in the COR domain as well as S1241 and T1287 in the 
kinase domain (Figure S1B-C) as phosphorylated residues. Importantly, with the 
exception of the LRRK1 T1287 site, none of the sites in LRRK2 were conserved in 
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LRRK1 and vice-versa (Figure 3B). Furthermore, none of the LRRK1 phosphosites 
represent predicted 14-3-3 binding motifs (assessed by Eurkaryotic Linear motif 
analysis: http://elm.eu.org/, (Yaffe et al., 1997) suggesting that at least for 14-3-3 
binding the differential protein interactions are likely related to differential 
phosphorylation sites in LRRK1 and LRRK2.   
 
The LRRK2-IN-1 kinase inhibitor induces dephosphorylation of LRRK2 but not 
LRRK1 
Given that LRRK2 is dephosphorylated in cells by LRRK2 kinase inhibitors (Dzamko 
et al., 2010; Vancraenenbroeck et al., 2014), we tested whether cellular treatment with 
LRRK2-IN-1 (Deng et al., 2011) affects the overall phosphorylation of LRRK1 via 
metabolic labeling. As shown in Figure 3A, both LRRK1 and LRRK2 are labeled 
with 
32
P. As expected, treatment of cell lines expressing 3xFlagLRRK2 with 1 µM of 
IN1 for 90 minutes resulted in a 90% reduction in LRRK2 phosphorylation, while 
treatment of cells expressing 3xFlag-LRRK1 did not affect LRRK1 phosphorylation 
levels (Figure 3B).  
 
Epidermal growth factor treatment induces translocation of LRRK1 to 
endosomes independent of LRRK2 
LRRK1 has previously been shown to translocate to endosomes upon treatment of 
HeLa cells with EGF (Hanafusa et al., 2011). This occurs through activation of the 
endogenous EGF-R receptor, which is expressed in SH-SY5Y cells (Michaelis et al., 
2008), and is therefore an observable cellular phenotype of the LRRK1:EGF-R 
interaction.  
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Treatment of SH-SY5Y cells stably expressing eGFP-LRRK1 with rhodamine labeled 
EGF (EGF-Rh), caused LRRK1 recruitment to EGF-Rh positive endosomes (Figure 
4B and S2), as expected. In our hands, approximately 50-60% cells responded 
between 15 and 30 minutes after stimulation with EGF (Figure 4C). However, EGF-
Rh stimulation of SH-SY5Y-eGFP-LRRK2 stable lines did not recruit LRRK2 to 
endosomes (Figure 4B). Importantly, LRRK2 knockdown (Figure 4A and B) did not 
affect LRRK1 recruitment (Figure 4B and C), demonstrating that the signaling of 
EGFR to LRRK1 is independent of LRRK2. Conversely, LRRK1 knockdown did not 
influence the lack of EGF-induced recruitment LRRK2 to endosomes, suggesting that 
LRRK2 does not take over LRRK1 functions in EGF-positive endosomes after 
LRRK1 depletion. Equivalent observations were made using non-labeled EGF 
(Figure S3). 
 
LRRK2-IN1 treatment induces translocation of LRRK2 to filamentous 
structures independent of LRRK1 
To ask whether LRRK1 was important for LRRK2 function, we used a LRRK2 
cellular phenotype induced by LRRK2 kinase inhibitor (IN1) treatment of LRRK 
expressing cells. LRRK2-IN1 treatment of LRRK2 expressing cells causes 
dephosphorylation of LRRK2, disrupts 14-3-3 binding and induces translocation of 
LRRK2 to filamentous structures (Dzamko et al., 2010; Deng et al., 2011; Hermanson 
et al., 2012). The selected dose of 1 µM LRRK2-IN1 is a minimal dose at which a full 
cellular effect is obtained, as measured by LRRK2-IN1 induced dephosphorylation of 
LRRK2. In our cell lines, the cellular IC50 of LRRK2-IN1 is ~0,3-0,4 µM and 1 µM 
corresponds to the IC90 (Vancraenenbroeck et al., 2014). Although we confirmed, as 
expected, that LRRK2-IN1 caused redistribution of LRRK2 in our stable cell lines, 
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LRRK2-IN1 did not affect LRRK1 localization (Figure 5). More importantly, genetic 
depletion of LRRK1 did not affect the LRRK2-IN1 induced translocation of LRRK2 
(Figure 5B-C). These results show that LRRK2 interaction with 14-3-3 and functional 
effects in cells are independent of LRRK1. 
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Discussion 
 
In this study, we compared the cellular functions of LRRK1 and LRRK2 by 
identifying their interaction partners using two different proteomic screening 
approaches, namely protein microarray and AP-MS (Figure 1). For the protein 
microarray approach, interactions between proteins are assessed in vitro by using 
recombinant proteins. As a consequence, protein microarrays can elucidate interactors 
which are independent of cellular environment as well as protein abundance. In 
comparison, the AP-MS approach isolates complexes from living cells and thus can 
reveal regulated interactions, for instance interactions depending on co-factors, post-
translational modifications or recruitment to specific cellular compartments. It should 
be noted though that isolated complexes are strongly dependent on the cell type or 
tissue that is used and this should also be taken into account for the interpretation of 
the results. Also, as for any screening methodology, results will include true hits as 
well as a certain proportion of false-positives and false-negatives. Therefore, results 
obtained with these screening experiments should be carefully interpreted and 
thoroughly validated. As a first validation step, we overexpressed LRRK1 or LRRK2 
in SH-SY5Y cell lines and tested their interaction (either on endougenous protein or 
after overexpression depending on the endogenous protein levels of the interactor 
tested) by CoIP. Our results confirm the LRRK1:EGF-R, LRRK2-14-3-3 interactions 
which were specific for each LRRK and Hsc70, BAG5 and Hsp90 as common 
interactors (Figure 2). 
 
Since, the previously reported interactions between LRRK1:EGF-R and LRRK2:14-
3-3 (Dzamko et al., 2010; Nichols et al., 2010; Titz et al., 2010; Hanafusa et al., 2011; 
Li et al., 2011) were the only ones identified with both screening methodologies, we 
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decided to focus on these two and study the potential crosstalk between LRRK1 and 
LRRK2 for these interactions. 
 
Previous studies reported that the phosphorylation status of LRRK2 is an important 
regulatory mechanism. LRRK2 is basally phosphorylated in cells (Greggio et al., 
2007; Ito et al., 2007; Berger et al., 2010; Taymans et al., 2011; 2013) with several 
phosphosites clustering in a region between the ankyrin and leucine-rich repeat 
domains (S910, S935, S955 and S973) (West et al., 2007; Gloeckner et al., 2010; 
Nichols et al., 2010; Beilina et al., 2014). These sites have generated much interest as 
their phosphorylation is reduced for several disease mutant forms of LRRK2 
(Dzamko et al., 2010; Nichols et al., 2010; Li et al., 2011). Since the LRRK2:14-3-3 
interaction is dependent on phosphorylation of LRRK2 at S910 and S935 (Nichols et 
al., 2010) we mapped LRRK1 and LRRK2 phosphosites in parallel and found that 
these map to distinct regions of the respective proteins: i.e. in the ANK, COR or 
kinase domains for LRRK1 and in the region linking the ankyrin repeat domain with 
the leucine rich repeat domain for LRRK2 (Figure S1B). In particular, LRRK1 is not 
phosphorylated in the ANK-LRR interdomain region, which mediates 14-3-3 binding 
in LRRK2, consistent with the lack of LRRK1 binding to 14-3-3. A further indication 
that LRRK1 and LRRK2 phosphosites are differentially regulated is their sensitivity 
to the LRRK2 IN-1 inhibitor (Deng et al., 2011). Treatment of cells in vitro with 
LRRK2-IN1 results in dephosphorylation of LRRK2 at the 14-3-3 binding sites: S910 
and S935 (Dzamko et al., 2010). Here we show via metabolic labeling that LRRK1 
phosphorylation is not significantly influenced by LRRK2-IN1 treatment, while 
LRRK2 was dephosphorylated under the same conditions (Figure 3). These observed 
differences between LRRK1 and LRRK2 suggest low LRRK1 off-target risks of 
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LRRK2 inhibition. Inhibition of the kinase function of LRRK2 is considered to have 
therapeutic potential (reviewed in (Greggio and Singleton, 2007; Vancraenenbroeck 
et al., 2011)), and the fact that dephosphorylation following LRRK2 kinase inhibition 
occurs for LRRK2 not LRRK1 suggest that targeting LRRK2 by kinase inhibitors 
without affecting LRRK1 is feasible. 
 
Both LRRK1:EGF-R and LRRK2:14-3-3 mediate cellular translocation of each 
LRRK: LRRK1 traffics together with EGFR to endosomes upon stimulation of the 
receptor with EGF (Hanafusa et al., 2011) while LRRK2 translocates to filamentous 
structures upon inhibitor-induced dephosphorylation and loss of 14-3-3 binding 
(Dzamko et al., 2010; Deng et al., 2011; Lobbestael et al., 2013). We exploited these 
cellular translocation properties to assess potential crosstalk between LRRK1 and 
LRRK2 cellular functioning. We first tested for overlap in the LRRK1 and LRRK2 
translocation phenotypes after treatment with LRRK2-IN1 or EGF. We saw that only 
LRRK2, and not LRRK1, translocated after LRRK2-IN1 treatment. Similarly, 
treatment with EGF did not affect the localization of LRRK2 while it was sufficient to 
translocate LRRK1 to endosomes. Furthermore, to exclude that the partner LRRK co-
regulates the translocation phenotype or that one LRRK may functionally take over 
the role of the partnering LRRK upon its depletion from the cell, we tested LRRK1 
and LRRK2 translocation after silencing of the partnering LRRK by RNAi. Here also, 
LRRK1 and LRRK2 translocation patterns remained unchanged, allowing us to 
conclude that the LRRK1:EGF-R and LRRK2:14-3-3 interactions mediate distinct 
cellular processes for each LRRK.  
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Despite the absence of crosstalk between LRRK1 and LRRK2 for these interactions, 
our proteomic screenings revealed also a number of shared interactors (Figure 1D, 
Tables 1C and 1F). Out of these, HSsc70 and Hsp90 (identified via AP-MS) and BAG 
proteins (identified using protein microarray) are related to protein stability, 
suggesting that folding and stabilization of LRRK proteins is crucial for their function. 
This is further supported by studies showing that LRRK2 and ROCO protein 
functions are multidomain proteins regulated by intramolecular interactions between 
domains with distinct folds (Greggio et al., 2008; Marín et al., 2008; Daniëls et al., 
2011). Hsp90 is reported to assist up to 10% of all cellular proteins and is heavily 
involved in conformational regulation of signaling proteins, including kinases (Li et 
al., 2012; Picard, 2012) and LRRK2 (Wang et al., 2008).  
Other shared interactors include proteins related to cytoskeleton such as tubulins 
(AP/MS) or to vesicular physiology such as the cyclin G activated kinase (GAK), the 
secretory protein chromogranin B or nerve growth factor VGF. Both LRRKs have 
already been functionally linked to vesicular physiology however so far these appear 
to be in different vesicular processes, such as receptor trafficking in endosomes for 
LRRK1 or autophagy or Golgi-related functions for LRRK2 (Beilina et al., 2014). 
LRRK2 has already been linked to cytoskeleton via the regulation of neurite 
morphology (Parisiadou et al., 2009; Law et al., 2014). Therefore, although this data 
indicates that there is no link between LRRK2 and endosomal trafficking of EGFR, 
LRRK2 may be involved in other vesicular processes as it was shown to co-localize 
with synaptic vesicles in cell culture and animal models, interact with Rab5, an early 
endosomal marker, and functionally associate with the synaptic vesicle endocytosis 
protein Endophilin A (Moore, 2008; Shin et al., 2008; Higashi et al., 2009; Dodson et 
al., 2012; Matta et al., 2012). We also show that LRRK2 does not respond to EGF 
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treatment, however LRRK2 is reported to play a role in mitogen-activated protein 
kinase (MAPK) signaling cascades (Gloeckner et al., 2009; Hsu, Chan, Greggio, et al., 
2010; Hsu, Chan, and Wolozin, 2010) which are downstream of growth factor 
receptors. Further work will be required to confirm these other interactions reported 
here and explore any functional links between LRRK1 and LRRK2 through these 
interactions. 
 
In conclusion, our comparative cellular study shows that, although LRRK1 and 
LRRK2 have a number of common interactors, there is no evidence for signaling 
crosstalk between the LRRK2 proteins at the level of two LRRK-specific cellular 
interactions LRRK1:EGF-R and LRRK2:14-3-3. Our work should stimulate further 
studies aiming at identifying similarities and differences in the cellular processes 
mediated by these 2 LRRK proteins, as these will provide further clues on the 
molecular steps by which LRRK2 causes Parkinson’s disease and LRRK1 does not. 
 
  
 25 
Acknowledgements 
The authors declare no conflict of interest. This study was supported by the Michael J. 
Fox Foundation (to J.-M.T., V.B., E.G. and M.R.C.). We thank the FWO (Research 
Foundation – Flanders)-Vlaanderen FWO project [number G.0666.09 (to V.B./J.-
M.T.)], research credit [number KAN2012 1.5.216.12 (to J.-M.T.)] and fellowships to 
L.R., E.L. and J.-M.T., the IWT (Agency for Innovation by Science and Technology) 
SBO/100042 to VB, the Belspo IAP 7/24 grant and the KU Leuven [grant numbers 
OT/08/052A and IOF-KP/07/ 001 (to V.B.) and GOA 12/016] for their support. 
M.G.D.G. was supported by P.O.R. SARDEGNA F.S.E. 2007-2013 - Obiettivo 
competitività regionale e occupazione, Asse IV Capitale umano, Linea di Attività 
l.3.1. This research was also supported in part by the Intramural Research Program of 
the National Institutes of Health, National Institute on Aging (to M.R.C.) and by the 
Fund Druwé-Eerdekens managed by the King Baudouin Foundation (to J.-M.T.). We 
also thank MIUR (Rientro dei Cervelli, lncentivazione alla mobilità di studiosi 
stranieri e italiani residenti all’estero) to EG and the CARIPLO Foundation (grant 
2011-0540). We thank Professor Johan Hofkens and Charlotte David (Molecular 
Imaging and Photonics, KU Leuven) for the use of the confocal laser scanning 
microscope. We also acknowledge the technical assistance of Fangye Gao and the 
Leuven Viral Vector Core 
(http://www.kuleuven.be/molmed/lvvc/vectorproduction.html) for the production of 
LV vectors. 
  
 26 
Figure legends 
 
Figure 1: Protein microarray screen for LRRK1 interactors. Recombinant 
3xFlag-eGFP or 3xFlag-LRRK1 generated as previously described (Civiero et al., 
2012) was used to probe protein microarrays containing ~9000 proteins. (A) Z-
binding score was determined for each protein as described in the materials and 
methods. Depicted here is a plot of the Z-scores of each protein for binding to LRRK1 
(x-axis) and LRRK2 (y-axis). Putative LRRK1 binding proteins are those that score 
high for LRRK1 binding (Z-scoreLRRK1 > 3) and low for eGFP binding (Z-scoreeGFP < 
3). Yellow lines indicate the cut-off Z-score values of 3 (Beilina et al., 2014). 
Affinity purification followed by mass spectrometry identification (AP-MS) of 
LRRK1 and LRRK2 interaction partners. Normal SH-SY5Y cells (mock) or SH-
SY5Ys stably expressing 3xFlag-eGFP, 3xFlag-LRRK1 or 3xFlag-LRRK2 (see 
materials and methods) were used to purify Flag immunoreactive cellular complexes 
using Flag-M2 agarose beads. (B) Isolated complexes were resolved on SDS-PAGE 
and visualized by coomassie brilliant blue staining. Bait proteins are indicated by blue 
boxes. (C) Schematic overview of the number of identified LRRK interactors and the 
overlap of hits between both proteins and both screening approaches. For a more 
detailed list of interactors see Supporting Tables 1A-C and 2A-C. 
 
Figure 2. Confirmation of specific interaction of LRRK1 with EGF-R and 
LRRK2 interaction with 14-3-3 and common interactors Hsc70, HSP90 and 
BAG5. Untransfected HEK293T cells (control) and HEK293T cell lines stably 
expressing 3xFlag-LRRK1 or 3xFlag-LRRK2 were transfected with EGF-R or 14-3-3. 
IP was performed using Flag antibody followed by immunoblotting with anti-EGF-R 
 27 
(A, bottom panel) and anti-14-3-3 (B, bottom panel). EGF-R interacts only with 
LRRK1 and not with LRRK2 while 14-3-3 CoIPs with LRRK2 but not with LRRK1. 
Inputs are shown in the upper panels. (C) To test three candidate common interactors 
of both LRRK1 and LRRK2, HEK 293T cells were transfected with 3xFlag-LRRK1, 
3xFlag-LRRK2 and GUS-3xFlag (control). After flag co-immunoprecipitations, 
samples were blotted and probed with anti-Hsc70, -Hsp90 and -BAG5 antibodies. All 
three proteins interact with both LRRKs. Molecular weight markers on the right of all 
blots are in kilodaltons. Data are representative of at least 5 independent experiments. 
 
Figure 3. LRRK1 and LRRK2 phosphorylation levels in cells after treatment 
with LRRK2-IN1 as measured by metabolic labeling. SH-SY5Y cells expressing 
3xFlag-LRRK1 or 3xFlag-LRRK2 were metabolically labeled with 
32
P. Cells were 
treated with LRRK2-IN1 (1 µM, 90 minutes) and LRRK1 and LRRK2 
phosphorylation levels were determined. Depicted are representative autoradiograms 
and immunoblots of the metabolically labeled samples after treatment with LRRK2-
IN1 (A). Quantification of the incorporated 
32
P levels in each experimental group is 
shown in (B) (Significance was assessed by an unpaired t-test, n = 3-4, ***: P<0,001).  
 
Figure 4. EGF-induced translocation of LRRK1 and LRRK2 after RNAi- 
mediated depletion of LRRK1 and LRRK2. (A) Western blot showing LRRK1 and 
LRRK2 expression levels in control and knockdown cell lines. (B-C) Cell lines were 
treated with EGF-rhodamine (EGF-Rh) and endosomal EGF-Rh was imaged together 
with eGFP-LRRK1 or eGFP-LRRK2 in order to quantify translocation of LRRK1 or 
LRRK2 to EGF-positive endosomes (see materials and methods). Depicted in panel 
(B) are representative confocal images with merged channels of DAPI, EGF-Rh and 
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eGFP-LRRK in basal conditions as well as 30 minutes after EGF-Rh treatment, both 
for the control cell lines (RNAi ctrl, top 2 rows of images) as well as for the 
knockdown cell lines: eGFP-LRRK1 with LRRK2 knockdown (sh3 construct, third 
row of images) and eGFP-LRRK2 with LRRK1 knockdown (sh1 construct, bottom 
row of images). Arrows point to LRRK-positive, EGF-Rh-positive endosomes, 
triangles indicate LRRK-negative, EGF-Rh-positive endosomes. Translocation of 
eGFP-LRRK1 by non-labeled EGF is given in supplemental Figure S3. Scale bar, 10 
µm for overview pictures and 5 µm for magnifications. (C) Quantification of the 
translocation LRRK1 or LRRK2 to EGF positive endosomes in the basal state, as well 
as after 5, 15 and 30 minutes of stimulation with EGF for the 4 different combinations 
tested was quantified as the % positive cells. Significance was assessed by 2-way 
ANOVA using experimental group (LRRK1 or LRRK2 cells, with control or 
knockdown of the partner LRRK) and time as factors, n=3. (statistically significant 
results after the Bonferroni post-hoc test comparing groups to the LRRK2 group are 
found in the LRRK1 control group: **: P<0,01, ***: P<0,001 as well as in the 
LRRK1 with LRRK2 RNAi group (###, P<0,001)).  
 
Figure 5. Assessment of LRRK2-IN1 induced translocation of LRRK1 and 
LRRK2. LRRK2-IN1 induced translocation of LRRK1 or LRRK2 to skein-like 
structures was assessed in SH-SY5Y cells stably expressing eGFP-LRRK1 or eGFP-
LRRK2 and together with control shRNA sequences or sequences for shRNA 
mediated knockdown of LRRK1 or LRRK2. (A) Confocal images of eGFP-LRRK1 
in SH-SY5Y cells after treatment with solvent or LRRK2-IN1 (10 µM, 90 minutes) 
showing diffuse cytoplasmic distribution of eGFP-LRRK1, unaltered by LRRK2-IN1. 
(B) Confocal images of eGFP-LRRK2 in SH-SY5Y cells after treatment with solvent 
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or LRRK2-IN1 (10 µM, 90 minutes) showing diffuse cytoplasmic distribution of 
eGFP-LRRK2 in cells treated with solvent and translocation of eGFP-LRRK2 to 
skein-like structures by LRRK2-IN1 treatment, both on control cells (shown here are 
cells with empty vector containing selection marker, BsdR) as well as in cells with 
LRRK1 knockdown (sh1 construct). Scale bar, 10 µM applies to all 
photomicrographs. (C) Quantification of cells with LRRK2-positive skein-like 
structures in 2 control cell lines (cells with empty vector containing selection marker, 
BsdR, and expressing a control short hairpin, miR ctrl) as well as 2 cell lines with 
LRRK1 knockdown (sh1 construct and sh2 construct). Significance was assessed by 
One-way ANOVA, Dunnett post-hoc test, n=3, ***: P<0,001) 
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